Abiogen Pharma and Oryx Pharmaceutical : A License Agreement for Disodium Clodronate.PISA Pisa (pē`sä), city (1991 pop. 98,928), capital of Pisa prov., Tuscany, N central Italy, on the Arno River. It is now c.6 mi (9.7 km) from the Tyrrhenian Sea, which once reached the city. , Italy -- The license agreement grants Oryx oryx (ôr`ĭks), name for several small, horselike antelopes, genus Oryx, found in deserts and arid scrublands of Africa and Arabia. They feed on grasses and scrub and can go without water for long periods. the exclusive license to market the speciality Clasteon (R) (the bisphosphonate bisphosphonate /bis·phos·pho·nate/ (bis-fos´fo-nat) diphosphonate. Bisphosphonate A class of drugs used to treat Paget's disease. Disodium di·so·di·um adj. Containing two atoms of sodium. Clodronate clodronate Ostac®, Bonefos® Metabolism A biphosphonate used to manage osteoporosis, Paget's disease of bone, cancer-induced hypercalcemia in Pts with prostate CA, myeloma and other CAs by regulating osteoclastic activity Therapeutic ) in Canada. Oryx Pharmaceutical Inc. launched Clasteon (R) 400 mg capsules in May 2004 and currently purchases the finished product from Abiogen which manufactures it at its new facility located in the industrial area of Pisa. Abiogen Pharma, born in 1997, is a fully integrated private Italian Pharmaceutical Company involved in R&D, Production and Marketing. Abiogen owns a prestigious R&D Pipeline and showed along the years significant skills in innovative compound development, also broadening out to the biotechnological field. Abiogen Pharma manufacturing plant, located in Pisa, occupies a surface of 100.500 m2, with a roofed surface of 27,500 m2 and is conceived in order to satisfy the new enhanced qualitative and manufacturing requirements. Oryx Pharmaceutical Inc. is a Canadian speciality pharmaceutical company serving the needs of Canadian health care professionals and patients through the licensing and commercialization of unique pharmaceutical products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion